Lexicon Pharmaceuticals, Inc. (LXRX) analyst actions
Rating and price-target actions on LXRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the LXRX overview →
2 measured LXRX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 | Press release | +1.91% | +5.13% | |
| Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss | Press release | -2.04% | -1.63% |
Keep exploring
More LXRX: earnings → · SEC filings → · LXRX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cidara Therapeutics, Inc. (CDTX) | 339 | +0.06% | 52% |
| DaVita Inc. (DVA) | 339 | +0.07% | 53% |
| Cellect Biotechnology Ltd. - American Depositary Shares (APOP) | 337 | -0.42% | 35% |
| Cardinal Health, Inc. (CAH) | 335 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.